Oxiracetam: Difference between revisions
Rabin Bista (talk | contribs) No edit summary |
Rabin Bista (talk | contribs) No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 3: | Line 3: | ||
| verifiedrevid = 464373213 | | verifiedrevid = 464373213 | ||
| IUPAC_name = (''RS'')-2-(4-hydroxy-2-oxopyrrolidin-1-yl)acetamide | | IUPAC_name = (''RS'')-2-(4-hydroxy-2-oxopyrrolidin-1-yl)acetamide | ||
| image = Oxiracetam. | | image = Oxiracetam Wiki Str.png | ||
| width = 120px | | width = 120px | ||
| image2 = | | image2 = Oxiracetam 3D.png | ||
| width2 = 120px | | width2 = 120px | ||
| imagename = 1 : 1 mixture (racemate) | | imagename = 1 : 1 mixture (racemate) | ||
| Line 49: | Line 49: | ||
| StdInChIKey = IHLAQQPQKRMGSS-UHFFFAOYSA-N | | StdInChIKey = IHLAQQPQKRMGSS-UHFFFAOYSA-N | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Oxiracetam''' ('''ISF 2522''') is a [[nootropic]] drug of the [[racetam]] family and very mild [[stimulant]].<ref>{{cite pmid | 20166767 }}</ref><ref>{{cite pmid | 3736279 }}</ref> Several studies suggest that the substance is safe even when high doses are consumed for a long period of time.<ref>{{cite pmid|2518332}}</ref><ref>{{cite pmid|3594458}}</ref><ref>{{cite pmid|3691580}}</ref> However, the [[mechanism of action]] of the [[racetam]] drug family is still a matter of research. Oxiracetam is not approved by [[Food and Drug Administration]] for any medical use in the United States. | '''Oxiracetam''' ('''ISF 2522''') is a [[nootropic]] drug of the [[racetam]] family and very mild [[stimulant]].<ref>{{cite pmid | 20166767 }}</ref><ref>{{cite pmid | 3736279 }}</ref> Several studies suggest that the substance is safe even when high doses are consumed for a long period of time.<ref>{{cite pmid|2518332}}</ref><ref>{{cite pmid|3594458}}</ref><ref>{{cite pmid|3691580}}</ref> However, the [[mechanism of action]] of the [[racetam]] drug family is still a matter of research. Oxiracetam is not approved by [[Food and Drug Administration]] for any medical use in the United States. | ||
| Line 72: | Line 75: | ||
==References== | ==References== | ||
{{reflist}} | {{reflist|2}} | ||
==External links== | ==External links== | ||
| Line 83: | Line 86: | ||
{{Glutamatergics}} | {{Glutamatergics}} | ||
[[Category:Drugs]] | |||
[[Category:Racetams]] | [[Category:Racetams]] | ||
[[Category:Pyrrolidones]] | [[Category:Pyrrolidones]] | ||
Latest revision as of 19:02, 7 April 2015
 | |
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Elimination half-life | 8 hours |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C6H10N2O3 |
| Molar mass | 158.155 |
| 3D model (JSmol) | |
| |
| |
  (what is this?) (verify) | |
|
WikiDoc Resources for Oxiracetam |
|
Articles |
|---|
|
Most recent articles on Oxiracetam |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Oxiracetam at Clinical Trials.gov Clinical Trials on Oxiracetam at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Oxiracetam
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Oxiracetam Discussion groups on Oxiracetam Patient Handouts on Oxiracetam Directions to Hospitals Treating Oxiracetam Risk calculators and risk factors for Oxiracetam
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Oxiracetam |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Oxiracetam (ISF 2522) is a nootropic drug of the racetam family and very mild stimulant.[1][2] Several studies suggest that the substance is safe even when high doses are consumed for a long period of time.[3][4][5] However, the mechanism of action of the racetam drug family is still a matter of research. Oxiracetam is not approved by Food and Drug Administration for any medical use in the United States.
Clinical findings
There has been effort put into investigating the possible use of oxiracetam as a medication to attenuate the symptoms of dementia.[6] However, no convincing results were obtained from studies where patients suffering from Alzheimer's dementia or organic solvent abuse were given 800 mg of the drug orally twice daily.[6]
The proven effects of the drug are limited to beneficial effects that lead to higher scores in tests for logical performance, attention, concentration, memory and spatial orientation. These tests were performed on patients with mild to moderate dementia and ADHD, and the doses were 800–2400 mg orally twice a day for one to six months. Improvement has also been seen in patients with exogenic post-concussion syndrome, organic brain syndromes and other dementias. According to V. Gallai et al, oxiracetam is more effective than piracetam for this purpose.[6]
Research shows oxiracetam improves hippocampally-mediated learning performance by increasing membrane-bound protein kinase C (PKC). When compared to control mice, oxiracetam-treated DBA mice demonstrated a significant increase in spatial learning performance as determined by the Morris water navigation task. This increase in performance was correlated to an increase in membrane-bound PKC.[7]
Pharmacokinetics
Oxiracetam is well absorbed from the gastrointestinal tract with a bioavailability of 56-82%.[8] Peak serum levels are reached within one to three hours after a single 800 mg or 2000 mg oral dose, with the maximal serum concentration reaching between 19-31 µg/ml at these doses. Oxiracetam is mainly cleared renally and thus 84% is excreted unchanged in the urine. The half-life of oxiracetam in healthy individuals is about 8 hours, whereas it is 10–68 hours in patients with renal impairment. There is some penetration of the blood–brain barrier with brain concentrations reaching 5.3% of that in the blood (measured one hour after a single 2000 mg intravenous dose).[6] Clearance rates range from 9 to 95 ml/min and steady-state concentrations when 800 mg is given twice daily range from 60 µM to 530 µM. The highest concentrations of oxiracetam is found in the septum pellucidum, followed by the hippocampus, the cerebral cortex and with the lowest concentrations in the striatum after a 200 mg/kg oral dose given to rats.[6]
See also
References
- ↑ PMID 20166767 (PMID 20166767)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ PMID 3736279 (PMID 3736279)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ PMID 2518332 (PMID 2518332)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ PMID 3594458 (PMID 3594458)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ PMID 3691580 (PMID 3691580)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ 6.0 6.1 6.2 6.3 6.4 PMID 8061686 (PMID 8061686)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand - ↑ Fordyce DE, Clark VJ, Paylor R, Wehner JM (February 1995). "Enhancement of hippocampally-mediated learning and protein kinase C activity by oxiracetam in learning impaired DBA/2 mice". PubMed.
- ↑ PMID 8061686 (PMID 8061686)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
External links
- Pages with script errors
- Pages with incomplete PMID references
- CS1 maint: Uses authors parameter
- Drugs with non-standard legal status
- Articles with changed CASNo identifier
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Infobox drug articles with non-default infobox title
- Chemical pages without DrugBank identifier
- Drugboxes which contain changes to verified fields
- Drugs
- Racetams
- Pyrrolidones
- Alcohols
- Acetamides
- Stimulants
- AMPA receptor agonists